Nuvalent Share Price Today
(NASDAQ: NUVL)

Name: Nuvalent Share Price Today (NASDAQ: NUVL) - Nuvalent Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Nuvalent share price is $72.03 & ₹6,264.38 as on 6 Mar 2025, 2.30 'hrs' IST

$72.03

▲

0.42

(0.59%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Nuvalent share price in Dollar and Rupees. Guide to invest in Nuvalent stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Nuvalent, along with analyst recommendations, forecasts, and comprehensive financials.

Nuvalent share price movements

Today's Low: $71.06
Today's High: $72.47
$72.03
1.34%
Downside
Day's Volatility :1.93%
Upside
0.6%
52 Weeks Low: $61.80
52 Weeks High: $113.51
$72.03
14.21%
Downside
52 Weeks Volatility :45.56%
Upside
36.54%

Nuvalent (NUVL) Returns

Period	Nuvalent, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-23.6%	2.1%	0.0%
6 Months	-15.71%	-4.1%	0.0%
1 Year	-15.22%	2.2%	0.0%
3 Years	348.12%	11.8%	-11.6%

Nuvalent (NUVL) Key Statistics

in dollars & INR

Previous Close	$71.61
Open	$71.89
Today's High	$72.465
Today's Low	$71.063
Market Capitalization	$5.1B
Today's Volume	$250.8K
52 Week High	$113.51
52 Week Low	$61.795
Revenue TTM	$0.0
Earnings Per Share (EPS)	$-3.93
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-29.46%

How to invest in Nuvalent Stock (NUVL) from India?

It is very easy for Indian residents to invest directly in Nuvalent from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Nuvalent stock in both Indian Rupees (INR) and US Dollars (USD). Search for Nuvalent or NUVL on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Nuvalent or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Nuvalent shares which would translate to 0.012 fractional shares of Nuvalent as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Nuvalent, in just a few clicks!

Returns in Nuvalent (NUVL) for Indian investors in Rupees

The Nuvalent stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Nuvalent investment value today

Current value as on today

₹90,236

Returns

₹9,764

(-9.76%)

Returns from Nuvalent Stock

₹14,727 (-14.73%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Nuvalent (NUVL)

-33%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Nuvalent Stock from India on INDmoney has decreased by -33% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Nuvalent

Deerfield Management Co
25.13%
FMR Inc
13.48%
Paradigm Biocapital Advisors LP
7.49%
Vanguard Group Inc
6.28%
BlackRock Inc
5.38%
Perceptive Advisors LLC
3.66%

Analyst Recommendation on Nuvalent

Buy

93%Buy

6%Hold

0%Sell

Based on 16 Wall street analysts offering stock ratings for Nuvalent(by analysts ranked 0 to 5 stars)

Based on 16 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Nuvalent Stock (NUVL)

What analysts predicted

Upside of 58.59%

Target:

$114.23

Current:

$72.03

Insights on Nuvalent Stock (Ticker Symbol: NUVL)

Price Movement
In the last 3 years, NUVL stock has moved up by 374.2%
NUVL vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 74.3%

Nuvalent Technicals Summary

Sell

Neutral

Buy

Nuvalent is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Nuvalent (NUVL) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Nuvalent, Inc.	-15.6%	-15.71%	-15.22%	348.12%	281.92%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Nuvalent, Inc.	NA	NA	NA	-4.71	-0.29	-0.19	NA	15.0
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Nuvalent, Inc.	Buy	$5.1B	281.92%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Nuvalent

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Organization	Nuvalent
Employees	142
CEO	Dr. James R. Porter Ph.D.
Industry	Services

Management People of Nuvalent

Name	Title
Dr. James R. Porter Ph.D.	CEO, President & Director
Prof. Matthew D. Shair Ph.D.	Founder, Head of Scientific Advisory Board & Director
Dr. Christopher D. Turner M.D.	Chief Medical Officer
Dr. Benjamin Lane Ph.D.	Senior Vice President of Technical Operations
Dr. Henry Pelish Ph.D.	Chief Scientific Officer
Ms. Deborah Ann Miller J.D., Ph.D.	Chief Legal Officer & Secretary
Mr. Matthew Metivier M.B.A.	Senior Vice President of Human Resources
Ms. Darlene Noci	Chief Development Officer
Mr. John Soglia Ph.D.	Senior Vice President of Translational Development

Important FAQs about investing in NUVL Stock from India :

What is Nuvalent share price today?

Nuvalent share price today stands at $72.03, Open: $71.89 ; Previous Close: $71.61 ; High: $72.47 ; Low: $71.06 ; 52 Week High: $113.51 ; 52 Week Low: $61.80.

The stock opens at $71.89, after a previous close of $71.61. The stock reached a daily high of $72.47 and a low of $71.06, with a 52-week high of $113.51 and a 52-week low of $61.80.

Can Indians buy Nuvalent shares?

Yes, Indians can invest in the Nuvalent (NUVL) from India.

With INDmoney, you can buy Nuvalent at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Nuvalent at zero transaction cost.

How can I buy Nuvalent shares from India?

It is very easy to buy Nuvalent from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Nuvalent (NUVL) be purchased?

Yes, you can buy fractional shares of Nuvalent with INDmoney app.

What are the documents required to start investing in Nuvalent stocks?

To start investing in Nuvalent, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.